VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $277,229 | +10.6% | 5,438 | +8.3% | 0.01% | +16.7% |
| Q2 2023 | $250,699 | +68.1% | 5,020 | +26.2% | 0.01% | +50.0% |
| Q1 2023 | $149,095 | -29.8% | 3,978 | -10.2% | 0.01% | -20.0% |
| Q4 2022 | $212,466 | +177.2% | 4,431 | +38.7% | 0.01% | +150.0% |
| Q3 2022 | $76,656 | +10.3% | 3,194 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $69,501 | +7.6% | 3,194 | +19.4% | 0.00% | +50.0% |
| Q1 2022 | $64,577 | -76.2% | 2,674 | -76.6% | 0.00% | -50.0% |
| Q4 2021 | $271,610 | -6.2% | 11,417 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $289,649 | +12.7% | 11,417 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $256,997 | +52.1% | 11,417 | +33.4% | 0.00% | +33.3% |
| Q1 2021 | $168,981 | +17.8% | 8,556 | +58.5% | 0.00% | +50.0% |
| Q4 2020 | $143,398 | -46.2% | 5,397 | 0.0% | 0.00% | -60.0% |
| Q3 2020 | $266,504 | – | 5,397 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |